Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

WT1 TCR-transduced T-cell therapy - Takara Bio

Next Previous
Drug Profile

WT1 TCR-transduced T-cell therapy - Takara Bio

Alternative Names: WT1 antigen-specific RetroNectin TCR gene therapy - Takara Bio; WT1 antigen-specific TCR-gene-transduced autologous lymphocytes - Takara Bio

Latest Information Update: 04 Nov 2017

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Takara Bio
  • Developer Mie University; Takara Bio
  • Class T lymphocyte cell therapies
  • Mechanism of Action Immunologic cytotoxicity; Immunostimulants; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Acute myeloid leukaemia; Myelodysplastic syndromes

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Acute-myeloid-leukaemia(Second-line therapy or greater) in Japan (SC)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Myelodysplastic-syndromes(Second-line therapy or greater) in Japan (SC)
  • 03 Dec 2016 Efficacy and safety data from a phase I trial in acute myeloid leukaemia and myelodysplastic syndrome presented at the 58th Annual Meeting and Exposition of the American Society of Hematology (ASH-2016)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top